The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance

References

• Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ−3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep 2016; 6:30799; PMID:27477870; http://dx.doi.org/10.1038/srep30799
   PubMed Web of Science ®Google Scholar
• Chang ML. Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol 2016; 22(4):1461-76; PMID:26819514; http://dx.doi.org/10.3748/wjg.v22.i4.1461
   PubMed Web of Science ®Google Scholar
• Hu JH, Chen MY, Yeh CT, Lin HS, Lin MS, Huang TJ, Chang ML. Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area. Medicine (Baltimore) 2016; 95(18):e3546; PMID:27149466; http://dx.doi.org/10.1097/MD.0000000000003546
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 2015; 30(7):1183-9; PMID:25678094; http://dx.doi.org/10.1111/jgh.12915
   PubMed Web of Science ®Google Scholar
• Chang ML, Hsu CM, Tseng JH, Tsou YK, Chen SC, Shiau SS, Yeh CT, Chiu CT. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol 2015; 30(2):329-36; PMID:25091195; http://dx.doi.org/10.1111/jgh.12705
   PubMed Web of Science ®Google Scholar
• Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45):26746-9; PMID:7592907; http://dx.doi.org/10.1074/jbc.270.45.26746
   PubMed Web of Science ®Google Scholar
• Duntas LH, Popovic V, Panotopoulos G. Adiponectin: novelties in metabolism and hormonal regulation. Nutr Neurosci 2004; 7(4):195-200; PMID:15682645; http://dx.doi.org/10.1080/10284150400009998
   PubMed Web of Science ®Google Scholar
• Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55(9):2319-26; PMID:22688349; http://dx.doi.org/10.1007/s00125-012-2598-x
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941):762-9; PMID:12802337; http://dx.doi.org/10.1038/nature01705
   PubMed Web of Science ®Google Scholar
• Li R, Lau WB, Ma XL. Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol Sin 2010; 31(10):1258-66; PMID:20802503; http://dx.doi.org/10.1038/aps.2010.95
   PubMed Web of Science ®Google Scholar
• Peta V, Torti C, Milic N, Focà A, Abenavoli L. Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. World J Hepatol 2015; 7(1):44-52; PMID:25624996; http://dx.doi.org/10.4254/wjh.v7.i1.44
   PubMedGoogle Scholar
• Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S, Blaha MJ, Martin SS, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 2016; 253:194-208; PMID:27498397; http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.897
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Blüher M, Stumvoll M. Adipokines in gestational diabetes. Lancet Diabetes Endocrinol 2014; 2(6):488-99
   PubMed Web of Science ®Google Scholar
• Wu ZJ, Cheng YJ, Gu WJ, Aung LH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 2014; 63(9):1157-66; PMID:24933398; http://dx.doi.org/10.1016/j.metabol.2014.05.001
   PubMed Web of Science ®Google Scholar
• Karas MG, Benkeser D, Arnold AM, Bartz TM, Djousse L, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, et al. Relations of plasma total and high-molecular-weight adiponectin to new-onset heart failure in adults ≥ 65 years of age (from the Cardiovascular Health study). Am J Cardiol 2014; 113(2):328-34; PMID:24169012; http://dx.doi.org/10.1016/j.amjcard.2013.09.027
   PubMed Web of Science ®Google Scholar
• Ye J, Liang Z, Liang Q, Zhang J, Mao S, Liang R. Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis. Lipids Health Dis 2015; 14:154; PMID:26612049; http://dx.doi.org/10.1186/s12944-015-0157-4
   PubMed Web of Science ®Google Scholar
• Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L. Increased circulating adiponectin in males with chronic HCV hepatitis. Eur J Intern Med 2015; 26(8):635-9; PMID:26293833; http://dx.doi.org/10.1016/j.ejim.2015.08.001
   PubMed Web of Science ®Google Scholar
• Hung CH, Lee CM, Chen CH, Hu TH, Jiang SR, Wang JH, Lu SN, Wang PW. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int 2009; 29(7):1086-93; PMID:19302182; http://dx.doi.org/10.1111/j.1478-3231.2009.01991.x
   PubMed Web of Science ®Google Scholar
• Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest 2011; 41(8):898-905; PMID:21539538; http://dx.doi.org/10.1111/j.1365-2362.2011.02498.x
   PubMed Web of Science ®Google Scholar
• Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008; 48(2):374-84; PMID:18666256; http://dx.doi.org/10.1002/hep.22387
   PubMed Web of Science ®Google Scholar
• Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46(1):66-73; PMID:17596870; http://dx.doi.org/10.1002/hep.21703
   PubMed Web of Science ®Google Scholar
• Derbala M, Rizk N, Al-Kaabi S, Amer A, Shebl F, Al Marri A, Aigha I, Alyaesi D, Mohamed H, Aman H, et al. Adiponectin changes in HCV-Genotype 4: Relation to liver histology and response to treatment. J Viral Hepat 2009; 16(10):689-96; PMID:19486470; http://dx.doi.org/10.1111/j.1365-2893.2009.01096.x
   PubMed Web of Science ®Google Scholar
• Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43:929-36; PMID:16139921; http://dx.doi.org/10.1016/j.jhep.2005.05.030
   PubMed Web of Science ®Google Scholar
• Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, Kao JH, Chen DS. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005; 43(2):235-42; PMID:15964656; http://dx.doi.org/10.1016/j.jhep.2005.02.044
   PubMed Web of Science ®Google Scholar
• Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008; 103(3):605-14; PMID:18190648; http://dx.doi.org/10.1111/j.1572-0241.2007.01729.x
   PubMed Web of Science ®Google Scholar
• Khattab MA, Eslam M, Shatat M, Abd-Aalhalim H, Mousa YI, Samir F, Aly H, Shaker O, Shaker Y. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J Gastrointestin Liver Dis 2012; 21(1):59-65; PMID:22457861
   PubMed Web of Science ®Google Scholar
• Lu JY, Chuang LM, Yang WS, Tai TY, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005; 25(4):752-9; PMID:15998426; http://dx.doi.org/10.1111/j.1478-3231.2005.1007.x
   PubMed Web of Science ®Google Scholar
• Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer 2011; 129(9):2226-35; PMID:21170963; http://dx.doi.org/10.1002/ijc.25861
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Fujiwara N, Tateishi R, Arano T, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, et al. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients. J Gastroenterol Hepatol 2015; 30(2):379-88; PMID:25168107; http://dx.doi.org/10.1111/jgh.12719
   PubMed Web of Science ®Google Scholar
• Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, Hershman DL, Brown RS, Jr, Neugut AI, et al. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology 2015; 88(1):57-68; PMID:25300295; http://dx.doi.org/10.1159/000367971
   PubMed Web of Science ®Google Scholar
• Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, Gieseler RK, Dienes HP, Canbay A. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009; 50(1):140-9; PMID:19019483; http://dx.doi.org/10.1016/j.jhep.2008.08.023
   PubMed Web of Science ®Google Scholar
• Saad Y, Ahmed A, Saleh DA, Doss W. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur J Gastroenterol Hepatol 2013; 25(8):920-5; PMID:23442415; http://dx.doi.org/10.1097/MEG.0b013e32835f2726
   PubMed Web of Science ®Google Scholar
• Degasperi E, Valenti L, Aghemo A, De Francesco R, Rumi M, Soffredini R, Donnici L, Cheroni C, Fargion S, Zanoni V, et al. Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. Antivir Ther 2014; 19(8):747-53; PMID:24523350; http://dx.doi.org/10.3851/IMP2743
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, et al. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57(3):534-40; PMID:22613000; http://dx.doi.org/10.1016/j.jhep.2012.04.027
   PubMed Web of Science ®Google Scholar
• Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT, Halt-C Trial Group. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8(5):458-62; PMID:20156586; http://dx.doi.org/10.1016/j.cgh.2010.01.022
   PubMed Web of Science ®Google Scholar
• Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54(3):795-802; PMID:15734858; http://dx.doi.org/10.2337/diabetes.54.3.795
   PubMed Web of Science ®Google Scholar
• Korah TE, El-Sayed S, Elshafie MK, Hammoda GE, Safan MA. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol 2013; 5(2):74-81; PMID:23646232; http://dx.doi.org/10.4254/wjh.v5.i2.74
   PubMedGoogle Scholar
• Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6(1):13-21; PMID:15655035; http://dx.doi.org/10.1111/j.1467-789X.2005.00159.x
   PubMed Web of Science ®Google Scholar
• Cook JR, Semple RK. Hypoadiponectinemia-cause or consequence of human “insulin resistance”? J Clin Endocrinol Metab 2010; 95(4):1544-54; PMID:20164291; http://dx.doi.org/10.1210/jc.2009-2286
   PubMed Web of Science ®Google Scholar
• Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR, Sung CM, Chen TH, Cheng ML, Chang KC, Chiu CT, et al. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLoS One 2014; 9(8):e104783; PMID:25122116; http://dx.doi.org/10.1371/journal.pone.0104783
   PubMed Web of Science ®Google Scholar
• Chang ML, Cheng ML, Chang SW, Tang HY, Chiu CT, Yeh CT, Shiao MS. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. Amino Acids 2017; 49(2):291-302; http://dx.doi.org/10.1007/s00726-016-2360-7
   PubMed Web of Science ®Google Scholar
• Chang ML, Kuo CJ, Huang HC, Chu YY, Chiu CT. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity. PLoS One 2016; 11(11):e0166712; PMID:27870883; http://dx.doi.org/10.1371/journal.pone.0166712
   PubMed Web of Science ®Google Scholar
• Kim WH, Hong F, Jaruga B, Hu Z, Fan S, Liang TJ, Gao B. Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-alpha receptor 1-independent and -dependent mechanisms. FASEB J 2001; 15(13):2551-3; PMID:11641261
   PubMed Web of Science ®Google Scholar
• Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47(6):2127-33; PMID:18446789; http://dx.doi.org/10.1002/hep.22269
   PubMed Web of Science ®Google Scholar